Prof Serge Gauthier
MD, FRCPC, Department of Neurology and Neurosurgery, Department of Psychiatry, Department of Medicine, McGill University and director of the Alzheimer Disease and Related Disorders Unit, McGill Centre for Studies in Aging, Verdun, Canada.
Professor Gauthier is also Associate Member, School of Physical and Occupational Therapy, McGill University; Associate Member, Institut Universitaire de Gériatrie, Universtity of Montreal; Member, Douglas Hospital Research Center; and Senior Scientist, Industry Programs Branch, Canadian Institutes of Health Research. For 30 years now, Professor Gauthier has lectured and published extensively on dementia and related topics.
Contributions to CNSforum by Prof Serge Gauthier:
09.06.2009
Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons
31.05.2009
Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder
24.04.2009
Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial
13.03.2009
Transient epileptic amnesia: regional brain atrophy and its relationship to memory deficits
17.02.2009
Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial
27.01.2009
Prodromal Alzheimer's disease: successive emergence of the clinical symptoms
21.11.2008
Imaging amyloid deposition in Lewy body diseases
31.10.2008
Vitamin B12 status and rate of brain volume loss in community-dwelling elderly
12.09.2008
Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial
18.08.2008
Long term effects of Aß42 immunisation in Alzheimer's disease: follow-up of a randomized, placebo-controlled phase I trial
31.07.2008
High risk of cognitive and functional decline after postoperative delirium. A three-year prospective study
30.06.2008
Safety and efficacy of galantamine in subjects with mild cognitive impairment
23.05.2008
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
16.04.2008
Donepezil treatment of patients with severe Alzheimer’s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial
31.03.2008
Conjugal Alzheimer disease: risk in children when both parents have Alzheimer disease
26.02.2008
Imaging of amyloid beta in Alzheimer's disease with (18)F-BAY94-9172, a novel PET tracer: proof of mechanism
31.01.2008
Dietary patterns and risk of dementia: The Three-City cohort study
08.10.2007
Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study
11.09.2007
Galantamine treatment of vascular dementia: a randomized trial
15.08.2007
Donepezil preserves cognition and global function in patients with severe Alzheimer disease
10.07.2007
Activities of daily living in frontotemporal dementia and Alzheimer disease
19.06.2007
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
22.05.2007
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study
30.04.2007
Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial
30.03.2007
Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study
22.02.2007
Conversion from subtypes of mild cognitive impairment to Alzheimer dementia
30.01.2007
Relation of higher folate intake to lower risk of Alzheimer disease in the elderly
24.11.2006
Improvement of episodic memory in persons with mild cognitive impairment and healthy older adults: evidence from a cognitive intervention program
26.10.2006
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
27.09.2006
Lewy bodies in the amygdala increase risk for major depression in subjects with Alzheimer disease
24.08.2006
Restriction in complex activities of daily living in MCI: impact on outcome
25.07.2006
Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD?
23.06.2006
Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer’s disease
23.05.2006
The characteristics of patients with uncertain/mild cognitive impairment on the Alzheimer Disease Assessment Scale-cognitive subscale
28.04.2006
Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study
22.03.2006
Inverse relationship between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans
20.02.2006
Cognitive impairment in patients with idiopathic normal pressure hydrocephalus
17.01.2006
Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life
22.11.2005
Delusions and hallucinations are associated with worse outcomes in Alzheimer Disease.
23.10.2005
Cerebral small-vessel disease and decline in information processing speed, executive function and memory
21.09.2005
Reduced risk of Alzheimer’s disease with high folate intake: the Baltimore Longitudinal Study of Aging
22.08.2005
APOE genotype, cholesterol level, lipid-lowering treatment, and dementia
26.07.2005
Donepezil for dementia in Parkinson’s disease: a randomized, double blind, placebo controlled, crossover study
16.06.2005
Atorvastatin for the treatment of mild to moderate Alzheimer disease
12.05.2005
Nighttime insomnia treatment and education for Alzheimer’s disease: a randomized, controlled trial
21.04.2005
The Montreal Cognitive Assessment, MOCA: a brief screening tool for Mild Cognitive Impairment
22.03.2005
Accuracy of self-reported depression in persons with dementia
18.02.2005
Distinctive clinical features of Mild Cognitive Impairment with subcortical cerebrovascular disease.
24.01.2005
Motor signs during the course of Alzheimer disease.
22.11.2004
Depressive symptoms increase the likelihood of cognitive impairment in elderly people with subclinical Alzheimer pathology.
22.10.2004
Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease
23.09.2004
Efficacy of donepezil in mild cognitive impairment
23.08.2004
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer’s disease.
28.07.2004
Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial.
16.06.2004
Cholesterol and APOE genotype interact to influence Alzheimer disease progression
24.05.2004
Effects of cholinergic drugs and cognitive training on dementia
20.04.2004
How heritable is Alzheimer’s disease late in life? Findings from Swedish twins
24.03.2004
Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B
23.02.2004
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil.
28.01.2004
Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease
17.12.2003
Rate of cognitive decline and mortality in Alzheimer’s disease.
21.11.2003
An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial.
27.10.2003
Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD
25.09.2003
Atrophy of the substantia innominata on Magnetic Resonance Imaging predicts response to donepezil treatment in Alzheimer’s disease patients.
22.08.2003
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization
28.07.2003
Five-year follow-up of cognitive impairment with no dementia
19.06.2003
Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial.
26.05.2003
Prospective study of alcohol consumption and risk of dementia in older adults
30.04.2003
Memantine in moderate-to-severe Alzheimer’s disease
21.03.2003
Impaired financial abilities in mild cognitive impairment
24.02.2003
Survival study of vascular dementia in Rochester, Minnesota
28.01.2003
Fluctuations in attention. PD dementia vs DLB with parkinsonism.
16.12.2002
Diagnostic profile of young and middle-aged memory clinic patients
25.11.2002
Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type.”
22.10.2002
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months
29.09.2002
Natural history of mild cognitive impairment in older persons.
20.08.2002
The prevalence of frontotemporal dementia